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Iron sucrose in hemodialysis patients: Safety of replacement
and maintenance regimens.
Background. Parenteral iron replacement and maintenance
are frequently required in hemodialysis patients. However, se-
rious adverse events have been reported after single doses of
some intravenous iron products. This multicenter phase IV clin-
ical trial examined the safety of iron sucrose for the treatment
of iron deficiency and for the maintenance of iron sufficiency in
hemodialysis patients.
Methods. In this safety study, iron sucrose was given in two
dosing regimens. Iron deficient patients were treated with intra-
venous iron sucrose, 100 mg, during 10 consecutive hemodialy-
sis sessions (replacement regimen). Iron replete patients were
given iron sucrose, 100 mg intravenous (iv) over 5 minutes,
weekly for 10 weeks (maintenance regimen). At the end of each
10-dose cycle, iron status was reassessed, and dosing during the
subsequent cycle was based on the adequacy of iron stores as
per Dialysis Outcome Quality Initiative (K/DOQI) Guidelines.
With each dosing regimen, adverse events, if any, were recorded
and described.
Results. Six hundred and sixty-five hemodialysis patients, in-
cluding 80 who had experienced previous intolerance to other
parenteral iron preparations, received a total of 8583 doses of
iron sucrose. One hundred eighty-eight patients received more
than one iv iron cycle (replacement, maintenance, or both).
There were no serious or life-threatening drug-related adverse
events.
Conclusion. Iron sucrose is safe when given as treatment for
iron deficiency or for maintenance of iron stores.
Hemodialysis patients require both iron replacement
and iron maintenance therapy to optimize management
of anemia. Because oral iron supplements are relatively
ineffective in correcting iron deficiency and maintaining
iron balance, clinical practice guidelines recommend ad-
ministration of intravenous iron [3].
Key words: iron sucrose, hemodialysis, anemia, iron deficiency, safety.
C© 2004 by the International Society of Nephrology
Though intravenous iron products are effective in the
treatment of the anemia of chronic kidney disease (CKD)
[6, 17], serious adverse drug events have been reported
with even single doses of some of these products [10, 16].
Iron sucrose has been used worldwide for more than 50
years [5]. Two multicenter studies have been performed
in the United States to evaluate the safety and efficacy
of iron sucrose injection in the treatment of dialysis-
associated anemia [6, 19]. No serious drug-related ad-
verse events or severe hypersensitivity reactions were
seen in either study. However, both studies were rela-
tively small, and both lacked information on maintenance
iron regimens. To date, no large-scale, multicenter, mul-
tidose study has been reported to examine the safety of
any intravenous iron compound given as repeated doses
by multiple dosing regimens in a patient-management
environment.
The current study was undertaken to examine the
safety of iron sucrose under usual clinical situations. Be-
cause anemia management commonly includes both iron
maintenance and iron replacement therapy, we sought to
obtain information on iron safety using both iron dosing
regimens. Accordingly, iron status was defined according
to K/DOQI guidelines [3]. If the patient was iron defi-
cient, the investigator used an iron replacement regimen.
If the patient was iron replete, a maintenance regimen
was used. Patients could receive multiple dosing cycles
and either dosing regimen, depending upon their current
iron status.
METHODS
Study design
This was a multicenter, open label, phase IV clin-
ical trial in hemodialysis patients who required both
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erythropoietin (EPO) and iron supplementation in ac-
cordance with the National Kidney Foundation K/DOQI
Clinical Practice Guidelines [3]. Each 100 mg dose of
iron sucrose (Venofer

, American Regent, Inc., Shirley,
NY, USA) was administered intravenously by iv injec-
tion, undiluted, at 20 mg/min over 5 minutes.
Patient selection
Men or women over the age of 18, able to give informed
consent, who were undergoing chronic hemodialysis 2 to
3 times weekly, and who met criteria [3] for parenteral
iron and epoetin alfa were enrolled in the study. Pa-
tients previously intolerant to other parenteral iron prod-
ucts such as iron dextran and/or ferric gluconate were
included. Pregnant or lactating women, patients with
other severe concomitant diseases including active infec-
tion, patients with causes of anemia not related to either
CKD or iron deficiency, or patients with a serum ferritin
>800 ng/mL and or transferrin saturation (TSAT) >50%
were excluded from enrollment in the study.
Drug regimens
Two dosage regimens of 10 doses of iron sucrose,
100 mg each dose, were given without a test dose. A re-
placement regimen (T) was given to patients who showed
evidence of iron deficiency [3]. A maintenance regimen
(M) was given to patients who were not iron deficient,
but required maintenance of their iron needs. Patients
received multiple dosing cycles and switched between re-
placement and maintenance cycles depending upon their
iron status over the course of the study.
Replacement regimen
Patients were given an iron replacement regimen if
baseline iron indices showed evidence of iron deficiency
(TSAT <20%, serum ferritin <100 ng/mL, or both).
These patients received 100 mg of iron sucrose at every
hemodialysis session for 10 sessions to correct iron de-
ficiency. At the end of a 10-dose cycle the patient’s iron
status was reevaluated no sooner than the dialysis day
after the last iv iron dose [6]. Based on TSAT and serum
ferritin values, patients received another replacement cy-
cle (if still iron deficient), were started on a maintenance
cycle (if TSAT was between 20% and 50% and serum fer-
ritin was between 100 and 800 ng/mL, or received no fur-
ther iron sucrose (TSAT >50% or ferritin >800 ng/mL).
Maintenance regimen
If TSAT was between 20% and 50% and the serum
ferritin was between 100 and 800 ng/mL, inclusive, then
a maintenance cycle was initiated and patients received
iron sucrose, up to 100 mg, once weekly for 10 weeks.
At the end of a 10-dose maintenance cycle, patients were
reevaluated. At that time, iron could be stopped, patients
could begin another maintenance cycle, or receive a re-
placement cycle to correct any iron deficiency, according
to K/DOQI guidelines [3].
Termination/end of study criteria
Enrolled patients continued to receive replacement or
treatment cycles according to the above protocol, based
on the K/DOQI guidelines. Patients were free to with-
draw from the study at any time. Patients experiencing a
serious or unacceptable adverse event, whether related
to the study drug or not, could be withdrawn at the discre-
tion of the investigator. In addition, patients requiring re-
nal transplantation or blood transfusion were withdrawn,
as were those who were noncompliant with study proce-
dures and protocols. The study was closed once sample
size projections had been reached. We determined that
a minimum of 460 patients would be adequate to detect
a single anaphylactoid event with 90% power at an ana-
phylactoid reaction incidence of 0.005%.
Adverse events
At each dialysis session during the treatment period,
and for 30 days after the last treatment dose was admin-
istered, we identified all serious adverse events and all
drug-related adverse events in study patients by physi-
cal examination and direct inquiry of patients and pa-
tient records, using forms encoded for coding symbols
for thesaurus of adverse events (COSTART). We defined
serious adverse events, levels of severity of nonserious ad-
verse events, and relationship of adverse event to study
drug according to standard guidelines for clinical trials
[1]. By these guidelines, a serious adverse event includes
any experience that is fatal or life-threatening, results in
or prolongs hospitalization, results in significant disability
or incapacity, is unusual, or, in the opinion of the inves-
tigator, presents a significant hazard to the patient. Simi-
larly, severity of adverse events is defined as follows: mild
if causing no limitation of usual activity, moderate if caus-
ing some limitation, severe if causing inability to carry out
usual activities. Relatedness of adverse events is defined
as none, unlikely (temporal relationship between study
drug and event is unclear and it is likely that the event can
be explained by the subject’s medical conditions or other
therapies, including dialysis), possible (some temporal re-
lationship between event and study drug administration,
and event unlikely to be explained by the subject’s med-
ical condition or other therapies), or probable (temporal
relationship is compelling and event cannot be explained
by the subject’s medical condition or other therapies).
We defined iron sucrose intolerance as the inability to
receive further iron sucrose therapy. It was the investi-
gator’s responsibility to identify, classify, and determine
relatedness of adverse events and to designate study sub-
jects as iron sucrose intolerant.
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Table 1. Summary of baseline patient demographics, by initial dosage
regimen
Initial dosage regimen
Characteristic Replacement Maintenance
Number of patients 337 (50.6%) 328 (49.3%)
Age y ± SD 59.9 ± 14.9 58.5 ± 15.8
(range 21–93) (range 21–92)
Sex M:F 194:143 207:121
Race (A:AA:C:H:O)a 10:133:153:37:4 5:159:133:29:2
Prior iron intolerance 58 22
aAsian: African American: Caucasian: Hispanic: Other.
Statistical methods
All patients who received any amount of study drug
were included in the safety analysis in an intent-to-treat
fashion. Descriptive statistics were performed on safety
parameters. Relative risks were calculated in order to de-
termine the ratio of the risk of hospitalization or death
per patient year due to infection in the iron sucrose
group as compared to the United States Renal Data
System (USRDS) historical control group [2, 4].
Chi-square tests were performed to calculate whether
the proportions were statically significantly different be-
tween the two groups. A P value ≤ 0.05 was deemed
statistically significant.
RESULTS
Patients
Six hundred and sixty-five patients were enrolled in the
study. A summary of the baseline patient demographics
is presented in Table 1. Eighty patients (12%) had a his-
tory of intolerance to an iron product administered prior
to study enrollment: 63 to iron dextran alone; 5 to ferric
gluconate alone; and 12 to both iron dextran and ferric
gluconate. The mean duration of iron therapy was 101.4
days (median 79 days, range 9 to 439 days). Seventy-five
percent of the patients remained on iron therapy for at
least 138 days. Overall, data for analysis included evalu-
ation of 239 patient years.
All 665 patients who received at least one dose of iron
sucrose were included in the safety analysis. Of the 665 pa-
tients, 264 patients (39.7%) received replacement therapy
for iron deficiency, 320 patients (48.1%) received main-
tenance regimens, while 81 patients (12.1%) received
both replacement and maintenance iron regimens. Six
hundred fifty-three patients were known to have been
iron sucrose naı¨ve, that is, not previously exposed to iron
sucrose; one patient had received iron sucrose prior to
study entry; and no specific information on iron sucrose
exposure was available on the remaining 11 patients.
Ninety-eight percent of the patients were receiving EPO
at baseline.
Table 2. Summary of dosing cycles
Dosing regimen
Parameter Replacement Maintenance Total
Number of doses 3910 4673 8583
Patients receiving 231 246 477 (71.7%)
1 cycle
Patients receiving 33 74 107 (16.0%)
2 or more cycles
Patients receiving both 81 (12.2%)
dosing regimens
Iron sucrose doses
A summary of iron sucrose dosing cycles is presented
in Table 2. A total of 8583 doses of iron sucrose were
administered; 3910 were given in replacement cycles and
4673 were administered in maintenance cycles. Forty-five
patients received cycles including 50 mg doses in contra-
vention of the study protocol. The average administered
dose for all study patients was 96.7 mg. Two hundred and
sixty-four patients (40%) received only replacement cy-
cles throughout the study. The majority of those patients,
231 individuals (87.5%), received only one complete re-
placement cycle. Thirty-three patients (12.5%) received
2 or more replacement cycles of iron sucrose. Only main-
tenance therapy was given to 320 patients (48.1%). Of
the patients receiving only maintenance regimens, 246
(76.9%) received one cycle, while 74 patients (23.1%)
received 2 or more cycles. Eighty-one patients (12%) re-
ceived both replacement and maintenance cycles.
Adverse events
Drug-related events. Six hundred sixty-five patients
were administered a total of 8583 doses of iron sucrose
throughout the study. There were no drug-related seri-
ous adverse events or deaths associated with iron sucrose.
There were 29 nonserious drug-related events reported
in 21 patients, yielding a nonserious adverse drug event
(ADE) per-patient incidence of 4.4%, and a per-exposure
incidence of 0.34%. Taste disturbance occurred in 0.13%
of exposures and 0.17% of patients. Excluding taste dis-
turbance, the nonserious ADE per-patient incidence was
2.7%, and the per-exposure incidence was 0.2%. The in-
cidence of nonserious drug-related adverse events asso-
ciated with administration of 50 mg doses did not differ
significantly compared to those associated with 100 mg
doses. A complete list of drug-related nonserious adverse
events is presented in Table 3. Two patients, one who com-
plained of pruritus on the days of the tenth replacement
dose and first maintenance dose, and one who complained
of constipation which preceded the fourth maintenance
dose and persisted 10 days, were withdrawn from the
study because of nonserious adverse events which their
investigators considered related to study drug. These two
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Table 3. Nonserious adverse drug events (ADE)a
Severity Incidence
Description #Events Mild Moderate Severe Per exposureb Per patientc
Constipation 3 1 1 1 0.00035 0.0045
Hypotension 3 0 3 0 0.00035 0.0045
Pruritis 2 2 0 0 0.00023 0.0030
Vomiting 3 0 3 0 0.00035 0.0045
Transaminase elevation 1 0 1 0 0.00012 0.0015
Dermatitis 1 1 0 0 0.00012 0.0015
Diarrhea 1 0 1 0 0.00012 0.0015
Dizziness 1 1 0 0 0.00012 0.0015
Dry mouth 1 1 0 0 0.00012 0.0015
Nausea 2 0 2 0 0.00023 0.0030
Subtotals 18 6 1 0 0.00211 0.027
Taste disturbance 11 10 1 0 0.00128 0.0165
Totals 29 16 12 1 0.00339 0.0436
aSerious ADE = 0; b8583 total doses; c665 total patients; 5 had more than 1 event.
patients were not listed as drug intolerant and were not
precluded from further therapy.
Unrelated adverse events. The most common unrelated
severe adverse events in this study were congestive heart
failure (12 patients; 1.8%), sepsis (11 patients; 1.7%), my-
ocardial infarction (8 patients; 1.2%), chest pain, pneu-
monia, pulmonary edema, and cerebrovascular accident
(7 patients each; 1.1% respectively).
Death and infection. Fifty-four patients required hos-
pitalization for infection (226 hospitalizations per 1000
patient years). None of these events was considered re-
lated to the study drug. Twenty-eight study patients died
during the study period (mean duration 101 days, range
9 to 439 days) and a safety-reporting follow-up period
(30 days after the last dose of iron sucrose). Five deaths
were thought to be the result of infection (estimated
21 deaths/1000 patient years). No deaths were deemed
to be related to iron administration by the treating
physician.
The mortality rate from infection or sepsis of 21 deaths
per 1000 patient years was not significantly different from
the rate of 34.2 deaths per 1000 patient years observed by
the USRDS [2] among all hemodialysis patients reported
from 1995 through 1997 (relative risk 21/34.2 = 0.61, P =
0.08) (Fig. 1). The hospitalization rate from infection of
226.5 hospital admissions per 1000 patient years was sig-
nificantly lower than that the rate of 422 hospitaliza-
tions for infection per 1000 patient years observed by the
USRDS for all hemodialysis patients (relative risk
226.5/422 = 0.54, P < 0.001) (Fig. 1) [4].
Hypersensitivity reactions. There were no drug-related
hypersensitivity reactions (anaphylactic or allergic reac-
tions) in this study. One patient experienced anaphylac-
tic reaction to new dialysis tubing, unrelated to the study
drug. The patient continued in the study after the event,
received the remaining doses of the iron sucrose regimen
without incident and successfully completed the study.
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Fig. 1. Relative risk of mortality or hospitalization due to infection in
patients receiving iron sucrose in the Iron Sucrose Clinical Trial (ISCT)
compared to that observed among all United States hemodialysis pa-
tients (USRDS). Rates of infection-related mortality and hospitaliza-
tion in ISCT patients compared favorably with those in the general
USRDS population.
DISCUSSION
We report the results of a large, multiple-dose clinical
trial to determine the safety of iv iron sucrose for iron
replacement, iron maintenance, or both in patients un-
dergoing chronic hemodialysis. We examined the safety
of iron sucrose in a large cohort of hemodialysis patients
under conditions of repeated iron replacement and/or
maintenance administration that closely mimic the clini-
cal situation. The regimens adhered closely to published
K/DOQI criteria.
Iron sucrose administration was associated with no se-
rious drug-related adverse events. Thus, among 665 pa-
tients collectively administered over 8500 doses of iron
sucrose we found no serious ADE and no drug intol-
erance. Since 98% of the patients in this study had not
previously been exposed to iron sucrose, we calcu-
lated the per-patient and per-exposure incidence of
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non-serious ADE to be 4.4% and 0.34%, respectively.
Taste disturbance accounted for the majority of ADEs,
was mild, did not tend to recur on readministration,
and did not preclude further iron sucrose administration.
Excluding taste disturbance, the nonserious per patient
ADE rate was 2.7% and per exposure nonserious ADE
rate 0.2%. The observed rate of nonserious drug-related
hypotension (0.0004% of exposures and 0.004% of pa-
tients) was consistent with previous findings in smaller
studies showing no drug-related hypotension. No patient
with prior iron sensitivity to either iron dextran, ferric
gluconate, or both experienced a serious ADE.
These observations are consistent with previous stud-
ies of iron sucrose [6, 19]. However, comparing these
safety results to those obtained with other available iv
iron agents requires great caution. Clinical trials directly
comparing safety of iv iron agents have not been per-
formed. Thus, explicit comparisons between agents have
involved use of historical controls [16]. The historical lit-
erature on safety of iv iron agents, however, frequently
lacks information crucial to assessment of safety, includ-
ing the number of doses administered, dose size, and rate
of administration, whether patients were incident (not
previously exposed) or prevalent, detailed descriptions
of reactions, information on timing of reactions, distinc-
tions between serious (life-threatening or requiring ther-
apeutic intervention) and nonserious adverse reactions,
and definitions of drug intolerance. In a recent report, for
example, four iron dextran historical control studies were
used to compare reaction rates observed in patients after
a noniron dextran agent given 125 mg iv over 10 min-
utes [16]. One of the control studies referred to unpub-
lished information on a dextran-coated iron hydroxide
(Feridex; Advanced Magnetics, Inc., Cambridge, MA,
USA; and Werner Stricker AG, Zollikofen, Switzerland)
used as an MRI contrast agent and lacking published
safety data at any dose [18]. A second study was lim-
ited to information on Imferon (Fisons, Loughborough,
UK), an iv iron dextran unavailable since 1991, admin-
istered primarily at doses of 250 to 500 mg in patients
without renal disease [14]. A third study was a retrospec-
tive trial lacking information on number of iron doses ad-
ministered [10]. The fourth, lacking direct information on
number of iron dextran doses administered, dose sizes or
rate of administration, or the number of patients treated,
relied on “reasonably accurate” commercial sales infor-
mation and voluntary reporting of allergic or anaphylac-
tic events to the World Health Organization [8].
More complete information on serious ADE after
iron dextran and ferric gluconate are, however, avail-
able. A retrospective analysis of a United States dialysis
provider database yielded 165 suspected serious ADEs
after 841,252 iron dextran doses, for a per-exposure se-
rious ADE rate of 0.02% [11]. A second retrospective
analysis of a United States dialysis provider database
(1,066,099 iron dextran doses in 48,509 patients) found
that iron dextran–associated life-threatening reactions,
identified as those requiring resuscitative medications,
were limited to incident patients receiving a test dose or
first therapeutic dose [abstract; Walters BAJ, Van Wyck
DB, J Am Soc Nephrol 12:418A, 2001]. Ferric gluconate
ADE rates have been examined prospectively in 2534 in-
cident (ferric gluconate naive) hemodialysis patients ad-
ministered a single 125 mg dose iv over 10 minutes [7].
A single life-threatening reaction was seen in one patient
(per-exposure and per-patient serious ADE rate 0.04%),
and drug intolerance was seen in 11 patients (drug intol-
erance per-exposure and per-patient ADE rate 0.44%).
Other reports assessing ADE rates after ferric gluconate
are from studies in which the patient enrollment was
much smaller [17], or the administered doses were larger
(≥250 mg) [12]. Information in patients given repeated
doses of ferric gluconate under replacement and main-
tenance regimens in hemodialysis patients is not, to our
knowledge, available.
Given the foregoing serious ADE rates reported for
iron dextran and iron sucrose, we performed post hoc
power tests to shed light on whether the current study
was sufficiently large enough to identify low-probability
adverse events. Post hoc calculations confirmed that if
the serious per-person ADE rate or the drug intolerance
ADE rate in the affected population had been 0.6%,
0.4%, or 0.2%, the probability that one or more seri-
ous reactions would have been encountered was 98% or
greater, 93% or greater, or 74% or greater, respectively.
Despite the results of prospective, multicenter trials
showing no relationship between iron dosing or body
iron status and bacteremia in dialysis patients, a biologi-
cally plausible relationship exists between all parenteral
iron treatment and infection [9, 15]. In the current study,
we found that the mortality rate from infection or sepsis
among patients of undergoing iron sucrose therapy com-
pared favorably with that of the overall United States
hemodialysis population. We also found that the hos-
pitalization rate from infection among patients receiv-
ing iron sucrose was significantly lower than that of the
general United States hemodialysis population. Differ-
ences in patient selection limited interpretation of these
results, however. Patients in the current clinical trial were
likely healthier at enrollment than are patients in the
general United States dialysis population. On the other
hand, although 100% of patients in the trial were exposed
to iv iron, only 55% to 60% of patients in the general
population received iv iron during the course of a year
[2, 4]. Nevertheless, our findings are in keeping with those
of a recent large, multicenter anemia trial [13], in which
hemodialysis patients randomized to normal compared
to subnormal hemoglobin targets required higher doses
of iv iron sucrose but suffered no increase in mortality.
Moreover, regardless of hemoglobin target, there was no
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difference in iron sucrose dose between survivors and
nonsurvivors.
CONCLUSION
This study demonstrates that iron sucrose is safe in the
treatment of iron deficiency and the maintenance of ad-
equate iron stores in EPO-treated dialysis patients, in-
cluding those sensitive to iron dextran, ferric gluconate,
or both.
APPENDIX
Additional members of the Iron Sucrose (Venofer) Clinical Tri-
als Group: Louis Ardon (Montgomery, AL); Mario Belledonne (Sil-
ver Spring, MD); Dinesh Chatoth (University of Arkansas, Little
Rock, AR); Thomas Crouch (Kansas City, MO); Piotr Tadeusz Dyk
(Wentzville, MO); John Elder (Santa Barbara, CA); Danny Fischer
(Cincinnati, OH); Leland Garrett (Raleigh, NC); Michael Germain
(West Springfield, MA); Carl Goldstein (Mountainside, NJ); Marvin
Greiff (Rochester, NY); Joseph Guzzo (Allentown, PA) Sally Hood
(Methuen, MA); Nathan Levin (New York, NY); Jim Lewis (Birming-
ham, AL); Norman Lunde (Arden Hills, MN); Edwin Macon (Emory
University, Atlanta, GA); Nawar Mansour (Memphis, TN); Kevin Mc-
Connell (Charlottesville, VA); Mary Meyer (Oregon Health Sciences
University, Portland, OR); Ellen Morrissey (San Pablo, CA); Ramakant
Mulay (Dyersburg, TN); Jesus Navarro (Tampa, FL); Clyde Pence (Pen-
sacola, FL); Russell Pikus (Columbus, IN); John Rastall (Vancouver,
WA); Denise Ricker (El Cerrito, CA); Allan Schwartz (Hahnemann
University, Philadelphia, PA); Warren Shapiro (Brooklyn, NY); Jef-
frey Silberzweig (The Rogosin Institute, Woodside, NY); James Ster-
rett (Paterson, NJ); Stephen Thomsen (Union City, NJ); James Van
Gelder (Hollywood, FL); Geoffrey Walker (Irving, TX); Duane Wom-
bolt (Norfolk, VA); Thomas Wooldridge (Tupelo, MS); Elaine Worces-
ter (University of Chicago, Chicago, IL); and Steven Zelman (Mt.
Vernon, IL).
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